These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34951573)

  • 1. Preparation of Long-Acting Somatostatin and GnRH Analogues and Their Applications in Tumor Therapy.
    Yu F; Zhang T; Fu F; Wang A; Liu X
    Curr Drug Deliv; 2022; 19(1):5-16. PubMed ID: 34951573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
    Rustgi SD; Oh A; Yang JY; Kang D; Wolin E; Kong CY; Hur C; Kim MK
    BMC Cancer; 2021 May; 21(1):597. PubMed ID: 34030646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
    Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
    BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
    Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
    Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
    Boucher JE; Sommers R
    Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
    Faggiano A
    J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
    Khagi S; Saif MW
    JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogs in pregnant patients with neuroendocrine tumor.
    Meoni G; Giommoni E; Petreni P; Pillozzi S; Mazzoni F; Pellegrini E; Brugia M; Lunghi A; Muto A; Antonuzzo L
    Anticancer Drugs; 2020 Nov; 31(10):1096-1098. PubMed ID: 32590392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
    Strosberg JR
    Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.
    Chicharro P; Paniagua A; Rodríguez-Jiménez P; Ibañes S; Cortina B; Riveiro J; Sampedro-Núñez MÁ; Fraga J; Marazuela M; Daudén E
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1887-1892. PubMed ID: 29377286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.